1. Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
   Naomi F. Lange et al, 2021, Journal of Hepatology CrossRef
2. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
   I. Walter et al, 2017, Medical Oncology CrossRef
3. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis
   Daniel Sepulveda-Crespo et al, 2021, Drugs CrossRef
4. Diabetes medications and risk of HCC
   Maria Corina Plaz Torres et al, 2022, Hepatology CrossRef
5. Hepatitis C and insulin action: An intimate relationship
   Hilla Knobler, 2016, World Journal of Hepatology CrossRef
6. Activation of peroxisome proliferator‐activated receptor‐gamma inhibits tumor growth by negatively regulating nuclear factor‐κB activation in patients with hepatocellular carcinoma
   Hiroyuki Nojima et al, 2016, Journal of Hepato-Biliary-Pancreatic Sciences CrossRef
7. Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
   Jerry R. Colca et al, 2017, Hepatology Communications CrossRef
8. Diabetes and Hepatitis C: A Two-Way Association
   Sara Salehi Hammerstad et al, 2015, Frontiers in Endocrinology CrossRef
9. Wheat-bran autolytic peptides containing a branched-chain amino acid attenuate non-alcoholic steatohepatitis via the suppression of oxidative stress and the upregulation of AMPK/ACC in high-fat diet-fed mice
   Takumi Kawaguchi et al, 2017, International Journal of Molecular Medicine CrossRef
10. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review
    Anne-Claire Desbois et al, 2017, World Journal of Gastroenterology CrossRef
11. Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
    Swati Katoch et al, 2022, World Journal of Gastroenterology CrossRef
12. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
    Rasha Youssef Hagag et al, 2022, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy CrossRef
13. Hepatitis C–Associated Diabetes Mellitus
    Ines Bilić-Ćurčić et al, 2017, Update on Hepatitis C CrossRef
14. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
    Waihong Chung et al, 2020, World Journal of Hepatology CrossRef
15. Mitochondrial Dysfunction in the Transition from NASH to HCC
    Mélissa Léveillé et al, 2019, Metabolites CrossRef